CRISPR Therapeutics AG $CRSP Shares Acquired by Vestmark Advisory Solutions Inc.
Vestmark Advisory Solutions Inc. lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 115.3% in the second quarter, according to the company in its most recent...
MarketBeat·6h ago
More News
CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a -2.56% change from its previous close.
Zacks·22h ago
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $9.00 by Analysts at Wedbush
Wedbush lowered their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an "outperform" rating on the stock in a report on Wednesday...
MarketBeat·1d ago
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
Zacks·3d ago
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
Zacks·4d ago
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
Zacks·5d ago
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
Zacks·5d ago
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Zacks·8d ago
CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $62.56, representing a -2.51% change from its previous close.
Zacks·10d ago
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.